---
title: "Eisai Q1 Net Income Rises"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294653443.md"
description: "Eisai Co. reported a 26% rise in Q1 net income to 18.24 billion yen, with operating profit up 19.2%. Revenue grew 15.6% to 234.33 billion yen. The company forecasts full-year 2026 revenue of 883.5 billion yen and net profit of 54 billion yen. Despite the strong results, Eisai shares fell 3.56% on the Tokyo Stock Exchange."
datetime: "2026-08-03T07:10:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294653443.md)
  - [en](https://longbridge.com/en/news/294653443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294653443.md)
generator: "portal-rs"
---

# Eisai Q1 Net Income Rises

Add  as your preferred news source on Google

 Add Now

Eisai Co. (4523.T,EII.SG) reported that its first-quarter profit attributable to owners of the parent increased 26.0% to 18.24 billion yen from 14.47 billion yen, prior year. Operating profit rose 19.2% to 24.73 billion yen from 20.74 billion yen. Earnings per share attributable to owners of the parent on a basic basis reached 64.71 yen compared with 51.35 yen. For the three-month period ended June 30, 2026, revenue increased 15.6% year-on-year to 234.33 billion yen, compared with 202.65 billion yen, a year earlier. 

For fiscal 2026, the company projects: revenue at 883.5 billion yen, representing 7.0% growth compared to the prior year. Operating profit is expected to reach 70 billion yen, up 58.6% year-on-year. Profit for the year is forecasted at 54 billion yen, up 33.3% from the previous year. Earnings per share attributable to owners of the parent on a basic basis is projected at 185.00 yen.

Eisai shares are trading at 4,656 yen on the Tokyo Stock Exchange, down 3.56%.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [4523.JP](https://longbridge.com/en/quote/4523.JP.md)

## Related News & Research

- [Eisai: Strong revenue and profit growth driven by key products and new market launches](https://longbridge.com/en/news/294650708.md)
- [How Investors May Respond To Eisai (TSE:4523) Advancing Lecanemab Data And New CNS Oncology Filings](https://longbridge.com/en/news/292407767.md)
- [What Eisai (TSE:4523)'s New Long‑Dated Bonds and UK Expansion Means For Shareholders](https://longbridge.com/en/news/289938779.md)
- [Coincheck Group N.V. GAAP EPS of ¥6.92, revenue of ¥114.33B](https://longbridge.com/en/news/296104610.md)
- [Weekly Recap: LEQEMBI IQLIK FDA approval and lecanemab SC bioequivalence](https://longbridge.com/en/news/293259150.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**